Analysts’ Weekly Ratings Updates for Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ: VERA) recently received a number of ratings updates from brokerages and research firms:

• 6/2/2026 – Vera Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $60.00 price target on the stock.
• 6/2/2026 – Vera Therapeutics had its “outperform” rating reaffirmed by William Blair.
• 6/2/2026 – Vera Therapeutics had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $90.00 price target on the stock.
• 6/2/2026 – Vera Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 5/15/2026 – Vera Therapeutics was given a new $91.00 price target by Evercore Inc.
• 4/20/2026 – Vera Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total value of $679,690.00. Following the transaction, the chief executive officer directly owned 216,744 shares of the company’s stock, valued at $7,963,174.56. This represents a 7.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.